Pharmacy News

PCSK9 inhibitors seem to benefit those with high cardiovascular risk

PCSK9 inhibitors appear to lower nonfatal myocardial infarction in adults with high or very high cardiovascular risk but not in those with low or moderate risk, according to a new study published in The BMJ.

How effective are antidepressants?

Antidepressants, including serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors, are widely used in the United States despite a number of unknowns related to their clinical performance. One of the biggest unknowns stems from the dearth of evidence on the efficacy of the drugs over the long term, as most studies have followed up with participants for only 8 to 12 weeks. Researchers also do not know much about how antidepressants affect mental and physical quality of life over time.

USPSTF issues update to aspirin use and CVD

The US Preventive Task Force (USPSTF) has updated its 2016 recommendation on the use of aspirin to protect against cardiovascular disease (CVD) and colorectal cancer (CRC).

More than 50% of people worldwide have headache disorders

More than 50% of people all over the world experienced a headache disorder in the past year, according to new research published in the Journal of Headache and Pain. The disorders—which include migraines, tension headaches, cluster headaches, and headaches related to things like exercise or sinusitis—affect 52% of people, the study found. Each day, an estimated 15.8% of the world’s population has a headaches, the researchers said.

FDA increases racial and ethnic diversity in clinical trials

FDA issued a draft guidance document for developing plans to enroll more participants in clinical trials from underrepresented racial and ethnic populations. The draft guidance advises sponsors of medical products to develop and submit a race and ethnicity diversity plan based on a framework outlined in the guidance to the agency early in clinical development.